A Benziodoxole-Based Hypervalent Iodine(III) Compound Functioning as a Peptide Coupling Reagent

1-Benzoyloxy-1,2-benziodoxol-3-(1H)-one (IBA-OBz), a readily available and bench stable benziodoxole-based iodine(III) reagent, can be employed for the synthesis of dipeptides from various standard and sterically hindered amino acids in the presence of (4-MeOC₆H₄)₃P. The combined system of IBA-OBz/(4-MeOC₆H₄)₃P is also successfully applied to the solid-phase peptide synthesis and a pentapeptide leu-enkephalin in unprotected form has been synthesized. Density functional theory calculations reveal that the rate-limiting step is nucleophilic attack of 4-dimethylaminopyridine (DMAP) onto IBA-OBz.

Introduction

Hypervalent iodine reagents have attracted considerable attention of synthetic chemists due to their rich reactivities, low toxicity, ready, availability, and recyclability (Varvoglis, 1997; Zhdankin and Stang, 2002, 2008; Wirth, 2005; Brown et al., 2013; Singh and Wirth, 2014; Zhdankin, 2014; Duan et al., 2016; Li et al., 2016; Yoshimura and Zhdankin, 2016; Han and Zhang, 2018; Liu et al., 2019). In 2012, we first reported that iodosodilactone, a bicyclic benziodoxole compound, could function as a coupling reagent to promote the efficient syntheses of esters, macrocyclic lactones, amides, and peptides in the presence of PPh₃ at 60^oC (Scheme 1) (Tian et al., 2012). We subsequently designed and synthesized a new powerful analog of iodosodilactone, FPID, which could mediate the peptide coupling reactions of standard amino acids and sterically hindered amino acids in good to high yields within 30 min in the presence of (4-MeOC₆H₄)₃P at room temperature (Scheme 1B) (Zhang et al., 2015). Recently, we successfully applied this system to the solid-phase peptide synthesis and cyclic peptide synthesis (Liu et al., 2018). Notably, FPID can be readily regenerated after reaction, and iodosodilactone shares the same feature, which is not provided in the existing peptide coupling reagents (Constable et al., 2007; EI-Faham and Albericio, 2011). Although FPID has the advantages of high efficiency, wide range of substrates ranging from standard amino acids to sterically hindered amino acids, and recyclability in peptide synthesis reactions, it should be prepared after four steps reaction of Suzuki coupling, diazotization/iodination, oxidation by potassium permanganate, and oxidation by aqueous sodium hypochlorite solution using commercially available 4-bromo-2,6-dimethylaniline and 3,5-bis(trifluoromethyl)-phenyl boronic acid as starting materials. Apparently, FPID is not readily available, which would have an adverse effect on its practical use. Thus, it is necessary to develop readily available and efficient iodine(III)-based peptide coupling reagents to promote their practical application in oligopeptide synthesis. IBA-OBz is a benziodoxole-based iodine(III) compound which can be prepared by one-step reaction from a commercial available I(III) compound IBA-OAc. We speculated that the structure of IBA-OBz would have similarity to FPID when taking account of two benzoyloxy ligands attached to central iodine(III) atom, furthermore, we assumed that it would exhibit a similar reactivity to FPID in peptide coupling reaction. Herein, we reported that an efficient preparation of IBA-OBz and its synthetic utility as an efficient coupling reagent to promote the synthesis of dipeptides and the solid-phase peptide synthesis of a pentapeptide leu-enkephalin. (Scheme 1C).

SCHEME 1

Scheme 1. Peptide Synthesis Mediated by Hypervalent lodine(lll) Reagents. (A) Peptide coupling of standard amino acids mediated by iodosodilactone. (B) Peptide coupling of standard and sterically hindered amino acids mediated by FPID. (C) Peptide coupling of standard and sterically hindered amino acids mediated by IBA-OBz.

Results and Discussion

IBA-OBz was readily prepared via a single-step process (Scheme 2). On the basis of the previous method (Mocci et al., 2007), a ligand exchange reaction between commercially available IBA-OAc and benzoic acid (1.15 equiv) in anhydrous CHCl₃ [0.5 M of IBA-OAc] furnished IBA-OBz in 91% yield as a colorless solid. Notably, IBA-OBz could be prepared on a large scale (20 mmol, 5.9 g) in 81% yield and stored for 1 year at room temperature without detectable decomposition.

SCHEME 2

Scheme 2. Synthesis and X-ray crystal structure of IBA-OBz.

The structure of IBA-OBz was elucidated by means of NMR spectroscopy and X-ray crystallography (for details, see Figure S1 and Table S1). The ¹³C NMR signal for the carbon atom connected to the iodine(III) central atom was found at 118.8 ppm, which was in the typical region for hypervalent iodine(III) compounds. Moreover, the single crystal structure of IBA-OBz was firstly obtained from chloroform/diethyl ether. The X-ray crystallography revealed that the O2-I1-O3 bond angles (163.95°) was <180° and the O3-I1-C1 and O2-I1-C1 bond angles (84.40° and 79.68°, respectively) deviated from 90°, which demonstrated IBA-OBz had the distorted T-shaped structure.

We firstly chose Boc-_L-Phe-OH and H-_L-Leu-OMe·HCl as two model substrates to test whether IBA-OBz can mediate peptide synthesis (Table 1). To our delight, the desired dipeptide Boc-Phe-Leu-OMe was obtained in 66% yield within 10 min upon treatment with 1.2 equiv of IBA-OBz, 1.0 equiv of (4-MeOC₆H₄)₃P, and 3.0 equiv of TEA in DCE at room temperature (Table 1, entry 1). Subsequently various organic solvents including DCM, CHCl₃, THF, EtOAc, acetone, CH₃CN, toluene, and DMF were screened. However, none of these solvents gave better yields than that in DCE (entries 2–9). Thereafter, DCE was selected as the solvent of choice, and other organic bases were accordingly screened in DCE. The results showed that 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), DMAP, N,N-diisopropylethylamine (DIPEA), 4-methylmorpholine (NMM), N-methylimidazole (NMI), and 4-pyrrolidinopyridine gave the product in 30–80% yields, in which DMAP was the best one (entries 10–15). When 1.5 equiv of both IBA-OBz and (4-MeOC₆H₄)₃P were used, the yield could be improved to 86% (entry 16). Therefore, we obtained the optimal reaction conditions in which 1.5 equiv of both IBA-OBz and (4-MeOC₆H₄)₃P and 3.0 equiv of DMAP were used in DCE (0.04 M) at room temperature.

TABLE 1

Table 1. Optimization of reaction conditions for Boc-Phe-Leu-OMe synthesis^a.

With the optimal conditions in hand, we first evaluated the performance of IBA-OBz for the synthesis of dipeptides from various standard amino acids (Table 2). All dipeptides were obtained in moderate to excellent yields within 10–20 min. This protocol was successfully applied to different amino protecting groups including Boc and Cbz, without detriment to yields (Table 2, entries 4, 5). Nevertheless, TEA was used instead of DMAP to avoid deprotection when amino protecting group was Fmoc (entry 6). When Cbz-Ala-OH was used as the carboxylic acid partner, moderate to high yields were obtained (entries 8–10). It is unnecessary to protect the indole ring of tryptophan in the peptide coupling reaction mediated by IBA-OBz (entry 13). Notably, for amino acids containing unprotected hydroxyl groups, such as serine (entry 17), threonine (entry 18) and tyrosine (entry 19), the use of TEA instead of DMAP could improve the coupling efficiency. Remarkably, reactions of sterically hindered amino acids such as valine (entries 20–22) and proline (entries 10, 22–26) also worked well, providing the corresponding dipeptides in yields up to 93%. Compared to peptide coupling reaction mediated by FPID, the reaction yields of Cbz-_L-Phe-_L-Thr-OMe (entry 18) and Boc-_L-Val-_L-Pro-OMe (entry 22) still needed to be improved.

TABLE 2

Table 2. IBA-OBz mediated synthesis of dipeptides from standard amino acids^a.

Sterically hindered amino acids such as N-methylamino acids and α,α-disubstituted amino acids are widely present in a variety of naturally occurring peptides and pharmaceuticals (the antihypertension drug lisinopril) (Slomczynska et al., 1992; Wenschuh et al., 1995; Humphrey and Chamberlin, 1997). However, the synthesis of peptides containing sterically hindered amino acids has limitation due to poor yields using conventional coupling reagents (i.e., DCC/HOBT) (Balasubramanian et al., 1981; Leibfritz et al., 1982). The existing processes generally require the preparation of activated amino acid derivatives to achieve the desired results (Katritzky et al., 2007; Brown and Schafmeister, 2008). Hence, we evaluated the IBA-OBz/(4-MeOC₆H₄)₃P system with several sterically hindered amino acids (Table 3). Most dipeptides were obtained in moderate to high yields within 10–60 min. It was worth noting that widely used amino protecting group Boc, which decomposed readily using BOP system, was compatible with the present reaction system (Table 3, entries 1–5). Coupling reactions between α,α-disubstituted amino acid (H-Aib-OMe) and a series of standard amino acids provided the corresponding dipeptides in 59–77% yields (entries 6–10). Notably, the coupling reaction proceeded smoothly even when both amino acids were sterically hindered, affording dipeptides in moderate to good yields (entries 11–13). Reactions of N-methylamino acids (Cbz-N(Me)-Phe-OH) with various standard amino acids produced the corresponding dipeptides in yields up to 91% (entries 14–22). Furthermore, coupling efficiency was improved by using TEA instead of DMAP when tyrosine was a component of dipeptides (entries 4, 22).

TABLE 3

Table 3. IBA-OBz mediated synthesis of dipeptides from sterically hindered amino acids^a.

In order to verify the application of IBA-OBz/(4-MeOC₆H₄)₃P system in the solid-phase peptide synthesis (SPPS), we chose unprotected Leu-enkephalin as the target short peptide, which was isolated from pig brains and had the effect of modifying neurotransmitters (Hughes et al., 1975; Coste et al., 1991). A commercially available 2-chlorotriphenylmethyl chloride resin (2-Cl-Trt-Cl Resin) was used as a carrier for the solid-phase peptide synthesis under standard conditions of Fmoc-solid-phase peptide synthesis (Fmoc-SPPS). The unprotected Leu-enkephalin was synthesized following the route (Scheme 3). The carboxylic group of Fmoc-Leu-OH was connected to 2-Cl-Trt-Cl resins to obtain the 2-chlorotrityl resin-bound Leu(Fmoc) (7a) in the presence of 3.0 equiv of N,N-diisopropylethylamine in DCM/N,N-dimethylformamide (DMF) (v/v = 1:1) within 4 h. The protecting group Fmoc was then removed from 7a upon the treatment of 20% piperidine/DMF within 30 min. Subsequently the peptide coupling reaction of Fmoc-Phe-OH with the 2-chlorotrityl resin-bound Leu produced 2-chlorotrityl resin-bound Leu-Phe dipeptide 7b using 3.0 equiv of IBA-OBz, 3.0 equiv of (4-MeOC₆H₄)₃P, and 3.0 equiv of TEA in DMF at room temperature within 2 h. The N-terminus of 7b was then sequentially extended with the Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Tyr-OH units using the standard Fmoc solid-phase peptide synthesis (SPPS) procedure to give 7c. After Fmoc group was removed from 7c, the pentapeptide chain was then cleaved from the resin upon the treatment of 0.5% trifluoroacetic acid/DCM to give the desired pentapeptide Leu-enkephalin. The Leu-enkephalin was purified by reversed-phase HPLC and it was finally obtained in moderate yield (44% over 10 steps). This successful synthesis of the N-,C-unprotected Leu-enkephalin demonstrated that the IBA-OBz/(4-MeOC₆H₄)₃P system was suitable not only in solution phase peptide synthesis but also in solid-phase peptide synthesis.

SCHEME 3

Scheme 3. Synthesis of unprotected Leu-enkephalin by solid-phase peptide synthesis.

To shed light on the reaction mechanism of this peptide bond formation reaction mediated by IBA-OBz, we performed DFT computations (Liu et al., 2009; Schoenebeck and Houk, 2010; Zhou and Li, 2015) to characterize the pathways for the reaction of Boc-Gly-OH and H-Gly-OMe·HCl with IBA-OBz (for details, see Supporting Information). As illustrated in Figure 1, the reaction would proceed through substitution of the OBz group of IBA-OBz with DMAP, generating zwitterion IM1 via TS1 by crossing a barrier of 27.4 kcal/mol (TS1). ESI-mass analysis of a reaction mixture containing IBA-OBz, DMAP, and (4-MeOC₆H₄)₃P in DCE under room temperature would yield a peak at m/z = 491.2082, which was assigned to be [IM1+H]⁺ (for details, see the Figure S2). Subsequently, the nucleophilic attack of (4-MeOC₆H₄)₃P to zwitterion IM1 resulted in zwitterion IM2 by crossing a barrier of 25.3 kcal/mol (TS2). The carboxylic group of Boc-Gly-OH would attack IM2 at the phosphorus center to give IM3, following with the leaving of benzoic acid anion via TS3 to produce IM4, which was predicted to require an activation free energy of 3.9 kcal/mol. Then, the IM4 was attacked by amino group of H-Gly-OMe to afford IM5, which had a barrier of only 4.6 kcal/mol. Subsequent (4-MeOC₆H₄)₃P=O dissociation through TS4 to generate dipeptide product II, which was calculated to have a barrier of only 0.8 kcal/mol. Reviewing all of the calculated energy profile, the overall reaction was exergonic by 80.8 kcal/mol and thus highly thermodynamically favorable. The formation of IM1 via TS1 constituted to be a rate-limiting step of the reaction with an energy barrier of 27.4 kcal/mol.

FIGURE 1

Figure 1. Energy diagram for IBA-OBz-mediated peptide formation calculated at the M06-2X/[6-311++G(2df,2p) + SDD(I)] (SMD)//M06-2X/[6-31+G(d) + Lanl2dz(I)] (SMD) level. Free energies are in kilocalories per mole, and bond lengths are in angstroms.

On the basis of experimental and computational studies, we proposed a reaction mechanism (Scheme 4). IBA-OBz was initially activated by DMAP to form the zwitterion IM1. Zwitterion IM1 then would undergo the ligand exchange with (4-MeOC₆H₄)₃P to give the zwitterion IM2, which reacted with the carboxylic group of Boc-Gly-OH to form a key intermediate acyloxyphosphonium intermediate IM4. Subsequently intermediate IM4 was attacked by the amino group of H-Gly-OMe to afford a dipeptide II and by-product tris(4-methoxyphenyl)phosphine oxide.

SCHEME 4

Scheme 4. Proposed mechanism for IBA-OBz/(4-MeOC6H4)3P mediated peptide-coupling reaction.

Conclusion

In conclusion, we reported a peptide coupling reaction mediated by a readily available, bench stable benziodoxole-based iodine(III) reagent IBA-OBz. In combination with tris(4-methoxyphenyl)phosphine and an organic base (DMAP or TEA), the reagent system not only effectively mediated the peptide coupling reaction of standard amino acids and sterically hindered amino acids in the solution-phase peptide synthesis, but also could be used in the solid-phase peptide synthesis. DFT calculations revealed that the formation of IM1 was a rate-limiting step of the peptide coupling reaction and the presence of IM1 was supported by its ESI mass spectrum.

Materials and Methods

Experimental and Computational Details

The ¹H NMR spectra were recorded at 400 MHz and ¹³C NMR spectra were measured at 100 MHz using a Bruker AV400 instrument with CDCl3 as the solvent. The chemical shifts (δ) were measured in ppm and with the solvents as references (For CDCl3, ¹H: δ = 7.26 ppm, ¹³C: δ = 77.00 ppm). The multiplicities of the signals are described using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, br = broad. High resolution mass spectral analyses (HRMS) were performed on a high resolution ESI-FTICR mass spectrometer (Varian 7.0 T). High performance liquid chromatography (HPLC) analysis was conducted using Shimadzu LC-10 AD coupled diode array-detector SPD-MA-10A-VP and chiral column of Daicel CHIRALCEL OD-H (4.6 mm−25 cm), AD-H (4.6 mm−25 cm), or AS-H (4.6 mm−25 cm). Melting points were recorded on a RY-1 type apparatus. All solvents were obtained from commercial sources and were purified according to standard procedures. Petroleum ether (PE), where used, had the boiling point range 60–90°C.

The M06-2X functional in conjugation with a mixed basis set of the Lanl2dz (Hay and Wadt, 1985) pseudopotential for iodine and 6-31G(d) for all other atoms was used for optimizing the geometry of all the minima and transition states in solution. The universal solvation model (SMD) was employed to account for the effects of DCE solution (Marenich et al., 2009). All the optimized structures were confirmed by frequency calculations to be either minima or transition states at the same level of theory. To obtain more accurate electronic energies, single point energy calculations were performed at the M06-2X/[6-311++G(2df, 2p) + SDD(I)](SMD) level with the M06-2X/[6-31G(d) + Lanl2dz(I)](SMD) structures. Computed structures were illustrated with CYLView (Legault, 2009). All quantum mechanical calculations were performed using Gaussian 16 packages (Frisch et al., 2016).

Chemical Synthesis

Synthesis of IBA-OBz

IBA-OAc (1.53 g, 5 mmol) and benzoic acid (702.1 mg, 5.75 mmol) were added to a 50 mL round-bottom flask, then CHCl₃ (15 mL) was added and the mixture was refluxed for 18 h. Then CHCl₃ was concentrated in vacuo and 30 mL of petroleum ether was added. The mixture was stirred at 60°C for 1 h, and filtered to give a crude product. The crude product was dissolved in CHCl₃, washed sequentially with NaHCO₃, H₂O, brine, and dried over anhydrous MgSO₄. The solvent was evaporated to give the desired product IBA-OBz (1.68 g, 91%).

Colorless solid; yield: 91%. ¹H NMR (400 MHz, CDCl₃) δ = 8.30 (dd, J = 7.6, 1.6 Hz, 1H), 8.13–8.08 (m, 3H), 8.01–7.97 (m, 1H), 7.76 (dd, J = 7.4, 0.4 Hz, 1H), 7.66–7.61 (m, 1H), 7.51 (d, J = 7.6 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ = 171.2, 168.1, 136.3, 133.5, 133.3, 131.4, 130.1, 129.2, 129.0, 128.8, 128.6, 118.8. HRMS(ESI): m/z calcd. for C₁₄H₉IO₄ [M+H]⁺: 368.9618, found 368.9604.

Synthesis of 3-1 to 3-26 and 6-1 to 6-22

To a mixture of PG-AA₁-OH (0.2 mmol) and H-AA₂-OMe·HCl (0.2 mmol) in DCE (5 mL) in a 25 mL round-bottom flask was added DMAP (0.6 mmol). The solution was stirred at room temperature for 5 min. Then, IBA-OBz(0.3 mmol) and (4-MeOC₆H₄)₃P (0.3 mmol) was added in sequence. The resulting mixture was stirred at room temperature and monitored by TLC. After 10 min, the reaction was quenched with saturated aq. sodium bicarbonate solution (10 mL) and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine, dried over anhydrous MgSO₄, and concentrated in vacuo to afford the crude product, which was then purified by silica gel flash chromatography to give the pure dipeptide product PG-AA₁-AA₂-OMe.

Boc-_L-Phe-_L-Leu-OMe (3-1)

Colorless solid; yield: 86%. ¹H NMR (400 MHz, CDCl₃) δ = 7.31–7.21 (m, 5H), 6.24 (d, J = 7.6 Hz, 1H), 4.99 (s, 1H), 4.58–4.54 (m, 1H), 4.35 (d, J = 6.8 Hz, 1H), 3.69 (s, 3H), 3.07 (d, J = 6.5 Hz, 2H), 1.63–1.41 (m, 12H), 0.92–0.88 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.8, 170.9, 155.4, 136.6, 129.3, 128.6, 126.9, 80.2, 55.6, 52.2, 50.7, 41.5, 38.0, 28.2, 24.6, 22.7, 21.8.

Boc-Gly-Gly-OMe (3-2)

Light yellow solid, yield: 81%. ¹H NMR (400 MHz, CDCl₃) δ = 6.59 (s, 1H), 5.12 (s, 1H), 4.07 (d, J = 5.6 Hz, 2H), 3.85 (d, J = 6.0 Hz, 2H), 3.76 (s, 3H), 1.46 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ = 170.2, 169.8, 156.1, 80.4, 52.4, 44.2, 41.0, 28.2.

Boc-_L-Leu-_L-Lys(Z)-OMe (3-3)

Colorless oily liquid; yield: 84%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.26 (m, 5H), 6.84 (s, 1H), 5.32 (d, J = 13.6 Hz, 1H), 5.12–5.03 (m, 3H), 4.56–4.53 (m, 1H), 4.16 (s, 1H), 3.71 (s, 3H), 3.23–3.11 (m, 2H), 1.80–1.26 (m, 18H), 0.90–0.89 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 173.1, 172.5, 156.5, 155.9, 136.5, 128.4, 128.2, 128.0, 80.0, 66.6, 52.8, 52.3, 51.9, 41.0, 40.4, 31.7, 29.0, 28.3, 24.6, 22.9, 22.4, 21.6.

Boc-_L-Leu-_L-Ala-OMe (3-4)

Colorless solid; yield: 85%. ¹H NMR (400 MHz, CDCl₃): δ = 6.63 (s, 1H), 4.91 (s, 1H), 4.60–4.52 (m, 1H), 4.11 (br s, 1H), 3.74 (s, 3H), 1.72–1.59 (m, 3H), 1.43 (s, 9H), 1.39 (d, J = 7.2 Hz, 3H), 0.93 (dd, J₁ = 6.2 Hz, J₂ = 4.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 173.1, 172.2, 155.6, 79.9, 52.4, 47.8, 41.3, 28.2, 24.6, 22.9, 21.9, 18.1.

Cbz-_L-Leu-_L-Ala-OMe (3-5)

Colorless solid; yield: 78%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.30 (m, 5H), 6.45 (d, J = 7.2 Hz, 1H), 5.18–5.11 (m, 3H), 4.58–4.54 (m, 1H), 4.20–4.19 (m, 1H), 3.75 (s, 3H), 1.72–1.50 (m, 6H), 1.40 (d, J = 7.2 Hz, 3H), 0.94 (d, J = 6.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 173.1, 171.8, 156.2, 136.2, 128.5, 128.1, 128.0, 67.0, 53.4, 52.4, 48.0, 41.5, 24.6, 22.9, 21.9, 18.1.

Fmoc-_L-Leu-_L-Ala-OMe (3-6)

Colorless solid; yield: 84%. ¹H NMR (400 MHz, CDCl₃) δ = 7.75 (d, J = 7.6 Hz, 2H), 7.58 (d, J = 5.6 Hz, 2H), 7.39 (d, J = 7.4 Hz, 2H), 7.30–7.26 (m, 2H), 6.62 (s, 1H), 5.36 (s, 1H), 4.59–4.53 (m, 1H), 4.44–4.34 (m, 2H), 4.25–4.19 (m, 2H), 3.73 (s, 3H), 1.67–1.55 (m, 3H), 1.39 (d, J = 7.2 Hz, 3H), 0.95–0.94 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 173.1, 171.7, 156.2, 143.8, 143.7, 141.3, 127.7, 127.1, 125.0, 120.0, 120.0, 67.0, 53.4, 52.5, 48.1, 47.2, 41.6, 24.6, 22.9, 22.0, 18.3.

Cbz-_L-Leu-_L-Lys(Z)-OMe (3-7)

Colorless solid; yield: 91%. ¹H NMR (400 MHz, CDCl₃) δ = 7.31–7.26 (m, 10H), 6.82 (d, J = 7.6 Hz, 1H), 5.38 (d, J = 7.6 Hz, 2H), 5.10–5.02 (m, 4H), 4.55–4.50 (m, 1H), 4.27–4.26 (m, 1H), 3.72 (s, 3H), 3.20–3.06 (m, 2H), 1.81–1.79 (m, 2H), 1.61–1.60 (m, 3H), 1.49–1.43 (m, 3H), 1.28–1.27 (m, 2H), 0.91–0.90 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ = 172.5, 172.5, 156.6, 156.3, 136.5, 136.1, 128.5, 128.5, 128.2, 128.1, 128.0, 67.0, 66.6, 53.3, 52.4, 51.9, 41.3, 40.3, 31.6, 29.0, 24.5, 22.9, 22.1, 21.8.

Cbz-_L-Ala-_L-His(Trt)-OMe (3-8)

Colorless solid; yield: 88%. ¹H NMR (400 MHz, CDCl₃) δ = 7.67 (d, J = 7.6 Hz, 1H), 7.36–7.26 (m, 16H), 7.11–7.08 (m, 6H), 6.54 (s, 1H), 5.63 (d, J = 6.8 Hz, 1H), 5.11–5.02 (m, 2H), 4.80–4.75 (m, 1H), 4.33–4.30 (m, 1H), 3.59 (s, 3H), 3.07–2.97 (m, 2H), 1.43–1.39 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.0, 171.3, 155.6, 142.1, 138.6, 136.4, 136.2, 129.6, 128.4, 128.0, 128.0, 127.9, 127.8, 119.6, 75.3, 66.6, 52.5, 52.1, 50.4, 29.4, 19.1.

Cbz-_L-Ala-_L-Cys(Trt)-OMe (3-9)

Colorless oily liquid; yield: 75%. ¹H NMR (400 MHz, CDCl₃) δ = 7.39–7.19 (m, 20H), 6.22 (d, J = 6.8 Hz, 1H), 5.29 (d, J = 8.8 Hz, 1H), 5.15–5.06 (m, 2H), 4.54–4.50 (m, 1H), 4.20 (s, 1H), 3.70 (s, 3H), 2.72–2.61 (m, 2H), 1.36 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.8, 170.5, 155.7, 144.2, 136.2, 129.4, 128.5, 128.1, 128.0, 126.9, 66.9, 52.6, 51.2, 50.2, 33.5, 18.8.

Cbz-_L-Ala-_L-Pro-OMe (3-10)

Colorless oily liquid; yield: 59%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.26 (m, 5H), 5.64 (d, J = 7.6 Hz, 1H), 5.08 (s, 2H), 4.55–4.51 (m, 2H), 3.72–3.61 (m, 5H), 2.24–2.17 (m, 1H), 2.10–1.96 (m, 3H), 1.39 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.3, 171.2, 155.6, 136.4, 128.4, 128.0, 127.9, 66.6, 58.6, 52.2, 48.2, 46.7, 28.8, 24.8, 18.2.

Cbz-_L-Met-Gly-OMe (3-11)

Colorless solid; yield: 77%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.26 (m, 5H), 6.70 (s, 1H), 5.55 (d, J = 7.2 Hz, 1H), 5.11 (s, 2H), 4.45–4.43 (m, 1H), 4.13–3.96 (m, 2H), 3.75 (s, 3H), 2.62–2.58 (m, 2H), 2.15–1.95 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.5, 170.0, 156.1, 136.0, 128.5 128.2, 128.0, 67.1, 53.7, 52.3, 41.1, 31.6, 29.9, 15.1.

Cbz-_L-Met-Gly-OEt (3-12)

Colorless solid; yield: 81%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.26 (m, 5H), 6.65 (s, 1H), 5.52 (s, 1H), 5.12 (s, 2H), 4.44–4.42 (m, 1H), 4.21 (d, J = 7.2 Hz, 2H), 4.10–4.06 (m, 1H), 4.00–3.94 (m, 1H), 2.60 (t, J = 7.0 Hz, 2H), 2.14–1.97 (m, 5H), 1.30–1.25 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.5, 169.5, 156.1, 136.0, 128.5, 128.1, 128.0, 67.0, 61.5, 53.6, 41.2, 31.6, 29.9, 15.1, 14.0.

Cbz-_L-Trp-_L-Leu-OMe (3-13)

Colorless oily liquid; yield: 80%. ¹H NMR (400 MHz, CDCl₃) δ = 8.07 (s, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.37–7.28 (m, 6H), 7.20 (t, J = 7.6 Hz, 1H), 7.14–7.10 (m, 2H), 6.00 (s, 1H), 5.50 (s, 1H), 5.13 (s, 2H), 4.53–4.47 (m, 2H), 3.65 (s, 3H), 3.37–3.34 (m, 1H), 3.19–3.14 (m, 1H), 1.69–1.35 (m, 7H), 0.84–0.81 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.8, 171.0, 155.9, 136.2, 128.5, 128.1, 128.0, 127.3, 123.5, 122.2, 119.7, 118.8, 111.2, 110.2, 66.9, 55.3, 52.2, 50.8, 41.4, 28.5, 24.6, 22.6, 21.9.

Cbz-_L-Asn(Trt)-_L-Leu-OMe (3-14)

Colorless solid; yield: 75%. ¹H NMR (400 MHz, CDCl₃) δ = 7.37–7.17 (m, 20H), 6.93 (s, 1H), 6.41 (d, J = 7.2 Hz, 1H), 5.14–5.07 (m, 2H), 4.57–4.53 (m, 1H), 4.47–4.42 (m, 1H), 3.70 (s, 3H), 3.07–3.03 (m, 1H), 2.69–2.64 (m, 1H), 1.58–1.48 (m, 2H), 1.43–1.38 (m, 1H), 0.87–0.84 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.8, 170.9, 170.4, 156.3, 144.2, 136.1, 128.6, 128.5, 128.1, 127.9, 127.0, 70.8, 66.9, 52.1, 51.1, 50.9, 40.6, 38.2, 24.7, 22.6, 21.7.

Cbz-_L-Phe-_L-Leu-OMe (3-15)

Colorless solid; yield: 84%. ¹H NMR (400 MHz, CDCl₃) δ = 7.38–7.19 (m, 11H), 6.25 (d, J = 7.6 Hz, 1H), 5.33 (d, J = 7.2 Hz, 1H), 5.13–5.06 (m, 2H), 4.50–4.43 (m, 2H), 3.69 (s, 3H), 3.15–3.02 (m, 2H), 1.80 (s, 1H), 1.39–1.25 (m, 1H), 1.11–1.00 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H), 0.79 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.7, 170.6, 155.9, 136.2, 136.1, 129.3, 128.6, 128.5, 128.1, 127.9, 126.9, 67.0, 56.5, 56.1, 52.0, 38.3, 37.7, 25.0, 15.2, 11.4.

Cbz-_L-Phe-_L-Tyr(Bzl)-OMe (3-16)

Colorless solid; yield: 73%. ¹H NMR (400 MHz, CDCl₃) δ = 7.42–7.16 (m, 19H), 6.88–6.81 (m, 4H), 6.17 (d, J = 7.2 Hz, 1H), 5.23 (d, J = 8.8 Hz, 1H), 5.08 (s, 2H), 4.99 (s, 2H), 4.75–4.71 (m, 1H), 4.40 (d, J = 6.4 Hz, 1H), 3.67 (s, 3H), 3.05–2.92 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ = 171.4, 170.3, 157.9, 155.8, 136.9, 136.2, 136.1, 130.2, 129.3, 128.6, 128.5, 128.5, 128.1, 127.9, 127.9, 127.7, 127.4, 127.0, 114.8, 69.9, 67.0, 55.9, 53.4, 52.2, 38.3, 37.0; HRMS(ESI): m/z calcd. for C₃₄H₃₄N₂O₆ [M+H]⁺: 567.2490, found 567.2486.

Cbz-_L-Phe-_L-Ser-OMe (3-17)

Colorless solid; yield: 60%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.25 (m, 10H), 7.20–7.18 (m, 2H), 6.68 (s, 1H), 5.25 (s, 1H), 5.08 (s, 2H), 4.57–4.55 (m, 1H), 4.43–4.38 (m, 1H), 3.91–3.88 (m, 2H), 3.75 (s, 3H), 3.10 (d, J = 6.8 Hz, 2H), 2.52 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.6, 170.5, 156.3, 136.2, 136.0, 129.3, 128.5, 128.4, 128.1, 127.9, 126.9, 67.0, 62.6, 56.1, 54.7, 52.6, 38.4.

Cbz-_L-Phe-_L-Thr-OMe (3-18)

Colorless solid; yield: 42%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.18 (m, 10H), 6.74 (d, J = 8.4 Hz, 1H), 5.40 (d, J = 8.0 Hz, 1H), 5.06 (s, 2H), 4.57–4.48 (m, 2H), 4.29–4.25 (m, 1H), 3.71 (s, 3H), 3.15–3.04 (m, 2H), 2.56 (d, J = 4.8 Hz, 1H), 1.12 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.7, 171.1, 156.1, 136.2, 136.0, 129.3, 128.5, 128.4, 128.1, 127.9, 126.9, 68.1, 67.0, 57.4, 56.1, 52.5, 38.2, 19.7.

Cbz-_L-Phe-_L-Tyr-OMe (3-19)

Colorless solid; yield: 84%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.23 (m, 8H), 7.14 (d, J = 6.8 Hz, 2H), 6.81 (d, J = 8.0 Hz, 2H), 6.64 (d, J = 8.4 Hz, 2H), 6.36 (s, 1H), 5.88 (s, 1H), 5.32 (d, J = 7.2 Hz, 1H), 5.06 (s, 2H), 4.77–4.73 (m, 1H), 4.42 (d, J = 6.8 Hz, 1H), 3.67 (s, 3H), 3.03–2.89 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.5, 170.8, 156.0, 155.3, 136.1, 130.3, 129.3, 128.6, 128.5, 128.2, 128.0, 127.0, 126.8, 115.5, 67.1, 55.9, 53.5, 52.3, 38.3, 37.0.

Boc-_L-Val-_L-Val-OMe (3-20)

Colorless solid; yield: 75%. ¹H NMR (400 MHz, CDCl₃) δ = 6.36 (d, J = 6.8 Hz, 1H), 5.04 (d, J = 8.4 Hz, 1H), 4.54 (dd, J = 8.8, 4.8 Hz, 1H), 3.92–3.88 (m, 1H), 3.73 (s, 3H), 2.22–2.12 (m, 2H), 1.44 (s, 9H), 0.97–0.90 (m, 12H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.1, 171.7, 155.8, 79.6, 59.9, 57.0, 51.9, 31.0, 30.6, 28.2, 19.1, 18.8, 17.9, 17.7.

Cbz-_L-Val-_L-Glu(OEt)-OEt (3-21)

Colorless solid; yield: 70%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.30 (m, 5H), 6.64 (d, J = 7.2 Hz, 1H), 5.38 (d, J = 7.6 Hz, 1H), 5.14–5.07 (m, 2H), 4.60–4.54 (m, 1H), 4.22–4.10 (m, 4H), 4.05–4.01 (m, 1H), 2.46–2.31 (m, 2H), 2.24–1.96 (m, 3H), 1.29–1.22 (m, 6H), 0.95 (dd, J = 16.4, 6.8 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ = 172.9, 171.4, 171.2, 156.3, 136.2, 128.5, 128.1, 128.0, 66.9, 61.6, 60.8, 60.2, 51.8, 31.2, 30.2, 26.9, 19.0, 17.7, 14.1, 14.0.

Boc-_L-Val-_L-Pro-OMe (3-22)

Colorless oily liquid; yield: 46%. ¹H NMR (400 MHz, CDCl₃) δ = 5.19 (d, J = 9.2 Hz, 1H), 4.52–4.49 (m, 1H), 4.28–4.24 (m, 1H), 3.78–3.61 (m, 5H), 2.25–2.17 (m, 1H), 2.06–1.91 (m, 4H), 1.40 (s, 9H), 1.01 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.4, 171.2, 155.8, 79.4, 58.7, 56.8, 52.1, 47.1, 31.3, 29.0, 28.3, 24.9, 19.2, 17.3.

Boc-_L- Pro-_L-Ala-OMe (3-23)

Colorless solid; yield: 84%. ¹H NMR (400 MHz, CDCl₃) δ = 7.31 (s, 0.64H), 6.56 (s, 0.35H), 4.54 (s, 1H), 4.29–4.20 (m, 1H), 3.72 (s, 3H), 3.54–3.32 (m, 2H), 2.30–2.12 (m, 2H), 1.86 (s, 2H), 1.45 (s, 9H), 1.37 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 173.1, 172.1, 171.6, 155.6, 154.5, 80.6, 80.3, 60.9, 59.7, 52.3, 47.9, 47.0, 30.8, 28.2, 24.5, 23.6, 18.5, 18.1.

Boc-_L- Pro-_L-Leu-OMe (3-24)

Colorless solid; yield: 93%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36 (s, 0.43H), 6.39 (s, 0.36H), 4.60–4.51 (m, 1H), 4.31–4.23 (m, 1H), 3.70 (s, 3H), 3.46–3.31 (m, 2H), 2.35–2.12 (m, 2H), 1.86 (s, 2H), 1.63–1.45 (m, 12H), 0.90 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 173.0, 172.3, 171.6, 155.8, 154.6, 130.8, 128.8, 80.3, 61.0, 59.5, 52.1, 50.7, 46.9, 41.3, 31.8, 31.4, 30.8, 30.1, 29.6, 29.6, 29.3, 28.2, 27.5, 24.8, 23.9, 22.8, 22.6, 21.7, 19.1, 14.0.

Boc-_L- Leu-_L-Pro-OMe (3-25)

Colorless oily liquid; yield: 63%. ¹H NMR (400 MHz, CDCl₃) δ = 5.11 (d, J = 8.8 Hz, 1H), 4.53–4.44 (m, 2H), 3.79–3.71 (m, 4H), 3.62–3.55 (m, 1H), 2.24–2.17 (m, 1H), 2.07–1.94 (m, 3H), 1.50–1.41 (m, 12H), 1.00–0.94 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.4, 171.8, 155.6, 79.4, 58.6, 52.1, 50.2, 46.6, 41.9, 28.9, 28.3, 24.8, 24.5, 23.3, 21.7.

Cbz-Gly-_L-Pro-OMe (3-26)

Colorless oily liquid; yield: 83%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.26 (m, 5H), 5.68 (s, 1H), 5.11 (s, 2H), 4.54–4.51 (m, 1H), 4.08–3.97 (m, 2H), 3.73 (s, 3H), 3.64–3.57 (m, 1H), 3.49–3.44 (m, 1H), 2.24–2.00 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.2, 166.9, 156.1, 136.4, 128.4, 127.9, 127.8, 66.7, 58.8, 52.2, 45.8, 43.2, 28.9, 24.5, 22.1.

Cbz-_L-Ala-Aib-OMe (6-1)

Colorless oily liquid; yield: 62%. ¹H NMR (400 MHz, CDCl₃) δ = 7.35–7.31 (m, 5H), 6.71 (s, 1H), 5.43 (d, J = 5.2 Hz, 1H), 5.10 (s, 2H), 4.25–4.21 (m, 1H), 3.71 (s, 3H), 1.57–1.51 (m, 6H), 1.36 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.7, 171.5, 156.0, 136.2, 128.5, 128.1, 127.9, 66.9, 56.4, 52.6, 50.4, 24.7, 24.6, 18.4.

Boc-Gly-Aib-OMe (6-2)

Colorless solid; yield: 72%. ¹H NMR (400 MHz, CDCl₃) δ = 6.70 (s, 1H), 5.20 (s, 1H), 3.76–3.73 (m, 5H), 1.55 (s, 6H), 1.45 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.8, 168.8, 156.1, 80.0, 56.4, 52.6, 44.4, 28.2, 24.7.

Boc-_L-Leu-Aib-OMe (6-3)

Colorless solid; yield: 67%. ¹H NMR (400 MHz, CDCl₃) δ = 6.65 (s, 1H), 4.84 (s, 1H), 4.05 (s, 1H), 3.72 (s, 3H), 1.69–1.64 (m, 3H), 1.57–1.50 (m, 6H), 1.45 (s, 9H), 0.95–0.92 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.7, 171.8, 155.8, 79.9, 56.2, 52.9, 52.4, 40.8, 28.2, 24.7, 24.6, 22.8, 22.0; HRMS(ESI): m/z calcd. for C₁₆H₃₀N₂O₅ [M+H]⁺: 331.2227, found 331.2227.

Boc-_L-Tyr-Aib-OMe (6-4)

Light yellow oily liquid; yield:70%. ¹H NMR (400 MHz, CDCl₃) δ = 7.07 (d, J = 8.0 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 6.30 (s, 1H), 5.65 (s, 1H), 5.10 (s, 1H), 4.22 (s, 1H), 3.72 (s, 3H), 3.04–2.88 (m, 2H), 1.46–1.43 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.6, 170.7, 155.6, 155.3, 130.5, 127.9, 115.5, 80.3, 56.4, 55.9, 52.6, 37.5, 28.2, 24.7, 24.5.

Boc-_L-Pro-Aib-OMe (6-5)

Colorless solid; yield: 81%. ¹H NMR (400 MHz, CDCl₃) δ = 7.47 (s, 0.44H), 6.48 (s, 0.45H), 4.26–4.14 (m, 1H), 3.71 (s, 3H), 3.47–3.32 (m, 2H), 2.33–1.85 (m, 4H), 1.53–1.46 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.6, 171.7, 171.1, 155.7, 154.4, 80.2, 61.0, 59.7, 56.0, 52.3, 46.8, 30.7, 28.2, 24.9, 24.6, 23.6.

Cbz-_L-Trp-Aib-OMe (6-6)

Colorless solid; yield: 77%. ¹H NMR (400 MHz, CDCl₃) δ = 8.28 (s, 1H), 7.71 (d, J = 6.0 Hz, 1H), 7.37–7.30 (m, 6H), 7.22–7.10 (m, 3H), 6.20 (s, 1H), 5.56 (d, J = 6.0 Hz, 1H), 5.12 (s, 2H), 4.51 (s, 1H), 3.67 (s, 3H), 3.36–3.33 (m, 1H), 3.17–3.11 (m, 1H), 1.35 (d, J = 5.6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.5, 170.3, 156.0, 136.2, 128.5, 128.1, 128.0, 127.3, 123.5, 122.3, 119.8, 118.9, 111.2, 110.4, 66.9, 56.3, 55.3, 52.5, 28.4, 24.7.

Cbz-_L-Phe-Aib-OMe (6-7)

Colorless solid; yield: 59%. ¹H NMR (400 MHz, CDCl₃) δ = 7.37–7.22 (m, 10H), 6.21 (s, 1H), 5.43 (d, J = 4.8 Hz, 1H), 5.09 (s, 2H), 4.37 (d, J = 6.4 Hz, 1H), 3.69 (s, 3H), 3.15–3.10 (m, 1H), 3.02–2.96 (m, 1H), 1.41 (d, J = 10.4 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.4, 169.8, 155.9, 136.5, 136.2, 129.4, 128.6, 128.5, 128.1, 127.9, 127.0, 66.9, 56.4, 56.2, 52.6, 38.6, 24.5, 24.4.

Boc-_L-Ala-Aib-OMe (6-8)

Colorless oily liquid; yield: 79%. ¹H NMR (400 MHz, CDCl₃) δ = 6.77 (s, 1H), 5.04 (s, 1H), 4.12 (s, 1H), 3.71 (s, 3H), 1.52 (d, J = 6.0 Hz, 6H), 1.44 (s, 9H), 1.32 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.8, 171.8, 155.7, 80.0, 56.3, 52.6, 49.9, 28.3, 24.8, 24.7, 17.8; HRMS(ESI): m/z calcd. for C₁₃H₂₄N₂O₅ [M+H]⁺: 289.1758, found 289.1759.

Cbz-_L-Met-Aib-OMe (6-9)

Light yellow oily liquid; yield: 63%. ¹H NMR (400 MHz, CDCl₃) δ = 7.35–7.29 (m, 5H), 6.75 (s, 1H), 5.58 (d, J = 7.6 Hz, 1H), 5.10 (s, 2H), 4.36–4.31 (m, 1H), 3.71 (s, 3H), 2.64–2.52 (m, 2H), 2.10–1.93 (m, 5H), 1.51 (d, J = 5.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.4, 170.2, 156.0, 136.1, 128.5, 128.1, 128.0, 67.0, 56.4, 53.6, 52.6, 31.5, 29.8, 24.9, 24.5, 15.0.

Cbz-_L-Ser(tBu)-Aib-OMe (6-10)

Colorless oily liquid; yield: 68%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.26 (m, 6H), 5.73 (s, 1H), 5.15–5.08 (m, 2H), 4.18 (s, 1H), 3.80–3.72 (m, 4H), 3.34 (d, J = 8.4 Hz, 1H), 1.54 (d, J = 8.0 Hz, 6H), 1.21 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.6, 169.4, 155.9, 136.2, 128.4, 128.1, 128.0, 74.1, 66.8, 61.6, 56.4, 54.1, 52.5, 27.3, 24.8, 24.5; HRMS(ESI): m/z calcd. for C₂₀H₃₀N₂O₆ [M+H]⁺: 395.2177, found 395.2182.

Cbz-_L-Val-Aib-OMe (6-11)

Colorless solid; yield: 46%. ¹H NMR (400 MHz, CDCl₃) δ = 7.35–7.28 (m, 5H), 6.50 (s, 1H), 5.39 (d, J = 7.2 Hz, 1H), 5.11 (s, 2H), 3.98–3.94 (m, 1H), 3.71 (s, 3H), 2.14–2.09 (m, 1H), 1.53 (s, 6H), 0.94 (dd, J = 16.8, 6.8 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.7, 170.3, 156.4, 136.2, 128.5, 128.1, 128.0, 67.0, 60.2, 56.5, 52.6, 31.1, 24.8, 24.5, 19.0, 17.7.

Cbz-_L-NMePhe-Aib-OMe (6-12)

Colorless oily liquid; yield: 72%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.11 (m, 10H), 6.50 (s, 0.6H), 6.22 (s, 0.3H), 5.15–5.07 (m, 1.7H), 4.94–4.78 (m, 1.5H), 3.72–3.67 (m, 3H), 3.32–3.27 (m, 1H), 2.97–2.86 (m, 4H), 1.48–1.42 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 174.4, 169.3, 169.0, 157.2, 155.9, 137.4, 137.2, 136.5, 136.0, 128.9, 128.4, 128.1, 127.9, 127.5, 126.5, 67.6, 67.3, 61.0, 59.9, 56.4, 56.2, 52.5, 52.4, 33.9, 33.7, 30.8, 30.2, 25.0, 24.7, 24.4.

Cbz-_L-NMePhe-_L-Val-OMe (6-13)

Colorless oily liquid; yield: 83%. ¹H NMR (400 MHz, CDCl₃) δ = 7.35–7.12 (m, 10H), 6.53 (d, J = 8.8 Hz, 0.6H), 6.23 (s, 0.3H), 5.16–5.07 (m, 1.8H), 4.98–4.95 (m, 1H), 4.86 (s, 0.3H), 4.52–4.49 (m, 1H), 3.71 (s, 3H), 3.36–3.27 (m, 1H), 3.07–2.50 (m, 4H), 2.16–2.07 (m, 1H), 0.86–0.79 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.8, 170.0, 169.7, 157.1, 155.9, 137.3, 137.1, 136.3, 135.9, 128.8, 128.4, 128.1, 127.9, 127.6, 126.5, 67.7, 67.4, 61.0, 60.1, 56.9, 52.0, 34.1, 33.8, 31.3, 31.0, 30.6, 18.8, 17.6, 17.4; HRMS(ESI): m/z calcd. for C₂₄H₃₀N₂O₅ [M+H]⁺: 427.2227 found 427.2228.

Cbz-_L-NMePhe-Gly-OMe (6-14)

Colorless oily liquid; yield: 90%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.13 (m, 10H), 6.58 (s, 0.7H), 6.27 (s, 0.3H), 5.14–4.87 (m, 3H), 4.15–4.04 (m, 1H), 3.92–3.87 (m, 1H), 3.73 (s, 3H), 3.38–3.33 (m, 1H), 3.03–2.87 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ = 170.5, 169.9, 157.2, 137.1, 136.3, 128.8, 128.4, 128.0, 127.9, 127.4, 126.5, 67.6, 67.3, 61.0, 59.9, 52.1, 41.0, 34.0, 33.8, 31.1, 30.4.

Cbz-_L-NMePhe-_L-Ala-OMe (6-15)

Colorless oily liquid; yield: 81%. ¹H NMR (400 MHz, CDCl₃) δ = 7.35–7.12 (m, 10H), 6.53 (s, 0.6H), 6.26 (s, 0.4H), 5.10–5.05 (m, 1.8H), 4.95–4.93 (m, 1H), 4.80 (s, 0.4H), 4.56–4.51 (m, 1H), 3.72 (s, 3H), 3.34–3.31 (m, 1H), 3.05–2.84 (m, 4H), 1.35–1.33 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.8, 169.7, 169.3, 156.9, 155.9, 137.3, 137.1, 136.4, 135.9, 128.8, 128.4, 128.0, 127.9, 127.5, 126.5, 67.6, 67.3, 61.0, 60.1, 52.3, 48.0, 34.0, 31.3, 30.6, 18.0; HRMS(ESI): m/z calcd. for C₂₂H₂₆N₂O₅ [M+H]⁺: 399.1914 found 399.1914.

Cbz-_L-NMePhe-_L-Ile-OMe (6-16)

Colorless oily liquid; yield: 86%. ¹H NMR (400 MHz, CDCl₃) δ = 7.36–7.10 (m, 10H), 6.55 (d, J = 8.0 Hz, 0.6H), 6.24 (d, J = 9.2 Hz, 0.3H), 5.15–5.07 (m, 1.7H), 4.98–4.94 (m, 1H), 4.84 (s, 0.3H), 4.56–4.53 (m, 1H), 3.70 (s, 3H), 3.62–3.28 (m, 1H), 3.07–2.85 (m, 4H), 1.86 (s, 1H), 1.40–1.29 (m, 1H), 1.10–1.01 (m, 1H), 0.89–0.82 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.7, 169.9, 169.6, 157.1, 155.9, 137.3, 137.1, 136.3, 135.9, 128.8, 128.4, 128.0, 127.9, 127.6, 126.5, 67.7, 67.4, 61.1, 60.2, 56.3, 51.9, 37.6, 34.1, 33.8, 31.3, 30.6, 24.9, 15.3, 11.4.

Cbz-_L-NMePhe-_L-His(Trt)-OMe (6-17)

Colorless oily liquid; yield: 87%. ¹H NMR (400 MHz, CDCl₃) δ = 7.32–7.07 (m, 27H), 6.53 (d, J = 4.0 Hz, 1H), 5.11–4.87 (m, 3H), 4.75 (d, J = 3.6 Hz, 1H), 3.59 (s, 3H), 3.44–3.39 (m, 1H), 3.15–2.88 (m, 3H), 2.81 (d, J = 14.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.3, 170.1, 169.9, 156.6, 155.8, 142.1, 138.6, 138.4, 137.6, 137.5, 136.5, 136.2, 129.5, 128.8, 128.7, 128.3, 128.2, 128.2, 127.9, 127.6, 127.6, 127.5, 127.2, 126.3, 126.2, 119.3, 119.2, 75.1, 67.1, 66.9, 61.0, 60.4, 52.6, 51.9, 33.9, 31.2, 30.9, 29.5, 29.1.

Cbz-_L-NMePhe-_L-Tyr(Bzl)-OMe (6-18)

Colorless oily liquid; yield: 90%. ¹H NMR (400 MHz, CDCl₃) δ = 7.40–7.07 (m, 15H), 6.96–6.80 (m, 4H), 6.45 (d, J = 7.6 Hz, 0.6H), 6.14 (d, J = 6.0 Hz, 0.3H), 5.12–4.89 (m, 5H), 4.78–4.77 (m, 1H), 3.71 (s, 3H), 3.28–3.23 (m, 1H), 3.14–3.04 (m, 1H), 2.96–2.86 (m, 2H), 2.64–2.59 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.5, 169.6, 169.3, 157.8, 157.6, 156.9, 155.6, 137.1, 137.0, 136.8, 136.2, 135.9, 130.0, 128.7, 128.4, 128.3, 128.0, 127.9, 127.8, 127.5, 127.2, 126.4, 115.0, 114.7, 69.7, 67.5, 67.3, 60.5, 59.6, 53.0, 52.2, 36.9, 36.7, 33.8, 33.6, 30.6, 30.0; HRMS(ESI): m/z calcd. for C₃₅H₃₆N₂O₆ [M+H]⁺: 581.2646 found 581.2642.

Cbz-_L-NMePhe-_L-Cys(Trt)-OMe (6-19)

Colorless oily liquid; yield: 80%. 1H NMR (400 MHz, CDCl3) δ = 7.33–7.01 (m, 25H), 6.52 (d, J = 6.8 Hz, 0.6H), 6.22 (d, J = 6.8 Hz, 0.4H), 5.05–4.73 (m, 3H), 4.38–4.34 (m, 1H), 3.59 (s, 3H), 3.23–3.18 (m, 1H), 2.92–2.67 (m, 4H), 2.60–2.56 (m, 1H), 2.47–2.42 (m, 1H); 13C NMR (100 MHz, CDCl3) δ = 170.3, 169.7, 169.5, 157.1, 155.8, 144.1, 137.2, 137.0, 136.2, 135.9, 129.3, 128.8, 128.4, 128.3, 127.9, 127.4, 127.1, 126.7, 126.5, 67.6, 67.4, 66.7, 66.6, 60.7, 59.6, 52.6, 52.4, 51.3, 34.0, 33.6, 33.5, 33.5, 31.1, 30.3; HRMS(ESI): m/z calcd. for C41H40N2O5S [M+H]+: 695.2550 found 695.2538.

Cbz-_L-NMePhe-_L-Lys(Z)-OMe (6-20)

Colorless oily liquid; yield: 88%. ¹H NMR (400 MHz, CDCl₃) δ = 7.33–7.10 (m, 16H), 6.56 (d, J = 7.2 Hz, 0.6H), 6.30 (d, 0.3H), 5.08–4.80 (m, 6H), 4.56–4.51 (m, 1H), 3.71 (s, 3H), 3.32–2.81 (m, 7H), 1.82–1.24 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.2, 170.1, 169.7, 156.9, 156.4, 137.2, 137.0, 136.5, 136.3, 128.8, 128.4, 127.9, 127.5, 127.1, 126.5, 67.3, 66.4, 60.9, 60.5, 52.4, 52.3, 51.9, 51.8, 40.4, 40.3, 34.0, 31.7, 31.1, 29.3, 29.0, 22.3, 22.1; HRMS(ESI): m/z calcd. for C₃₃H₃₉N₃O₇ [M+H]⁺: 590.2861 found 590.2862.

Cbz-_L-NMePhe-_L-Glu(OEt)-OEt (6-21)

Colorless oily liquid; yield: 82%. ¹H NMR (400 MHz, CDCl₃) δ = 7.33–7.08 (m, 10H), 6.71–6.61 (m, 1H), 5.08–5.02 (m, 1.6H), 4.95–4.89 (m, 1H), 4.78 (s, 0.4H), 4.52–4.51 (m, 1H), 4.19–4.06 (m, 4H), 3.33–3.28 (m, 1H), 3.08–2.82 (m, 4H), 2.31–2.21 (m, 3H), 1.96–1.90 (m, 1H), 1.26–1.19 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ = 172.6, 172.5, 171.2, 170.1, 169.9, 156.8, 155.8, 137.3, 137.0, 136.3, 135.9, 128.8, 128.4, 128.0, 127.9, 127.5, 126.5, 67.5, 67.3, 61.4, 61.2, 60.7, 60.5, 60.4, 51.9, 51.6, 34.1, 33.9, 31.5, 30.9, 30.1, 30.0, 27.0, 26.7, 14.0, 14.0; HRMS(ESI): m/z calcd. for C₂₇H₃₄N₂O₇ [M+H]⁺: 499.2439 found 499.2439.

Cbz-_L-NMePhe-_L-Tyr-OMe (6-22)

Colorless oily liquid; yield: 91%. ¹H NMR (400 MHz, CDCl₃) δ = 7.34–7.06 (m, 10H), 6.88–6.59 (m, 5H), 6.40 (s, 0.4H), 6.22–6.14 (m, 1H), 5.13–4.78 (m, 4H), 3.73–3.71 (m, 3H), 3.28–2.83 (m, 4H), 2.64–2.63 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 171.9, 171.7, 170.0, 169.6, 157.1, 155.3, 137.0, 136.7, 136.2, 135.7, 130.1, 128.8, 128.6, 128.5, 128.1, 128.0, 127.6, 127.0, 126.6, 67.8, 67.5, 60.7, 59.9, 53.2, 52.4, 37.1, 36.8, 33.8, 30.9, 30.3; HRMS(ESI): m/z calcd. for C₂₈H₃₀N₂O6 [M+H]⁺: 491.2177 found 491.2180.

General Procedure for Fmoc-SPPS Mediated by IBA-OBz

All Fmoc-protected amino acids and 2-chlorotrityl chloride resin (2-Cl-Trt-Cl resin, 0.98 mmol/g) were purchased and used without further purification. All peptides were synthesized using 200 mg resin in solid-phase peptide synthesis vessel. The synthetic route included immobilized the C terminal amino acid onto resin, deprotection, coupling, cleavage from resin, and purification of peptides.

Immobilized the C-Terminal Amino Acid Onto Resin

To a 5 mL round-bottom flask was added 2-Cl-Trt-Cl resin (0.196 mmol, 200 mg) and C-terminal Fmoc-amino acid (Fmoc-AA₁-OH, 0.6 mmol), then DCM and DMF (2 mL, v:v = 1:1) were added and the mixture was stirred at room temperature. Then DIPEA (0.1 mL) was added and the mixture was stirred at room temperature for 4 h. Afterward, the mixture was filtered and washed with MeOH (3 × 5 mL) and DCM (3 × 5 mL) in sequence. The resin was used for next step without any purification.

Blocked the Reaction Sites

To a 5 mL round-bottom flask was added the resin from last step and MeOH/DIPEA/DCM (2 mL, v:v:v = 1:2:7), the mixture was stirred at room temperature for 4 h. Afterward, the mixture was filtered and washed with MeOH (3 × 5 mL) and DCM (3 × 5 mL) in sequence. The resin was used for next step without any purification.

Deprotection of Fmoc

To a solid-phase peptide synthesis vessel was added the resin from last step and 20% piperidine/DMF (2 mL), the tube was capped and the mixture was shaken with air bubbling from the bottom of the reaction vessel by using air-pump at room temperature for 30 min. The mixture was filtered and washed with MeOH (3 × 5 mL) and DCM (3 × 5 mL) in sequence. The resin was used for next step without any purification.

Coupling

To a solid phase peptide synthesis vessel was added the resin from last step, Fmoc-AA₂-OH (0.6 mmol) and DMF (2 mL), then the mixture was shaken with air bubbling from the bottom of the reaction vessel by using air-pump. Afterward, TEA (0.6 mmol, 84 μL) was added. After 5 min, IBA-OBz (221 mg, 0.6 mmol) and (4-MeOC₆H₄)₃P (216 mg, 0.6 mmol) was added. After 2 h, the mixture was filtered and washed with MeOH (3 × 5 mL) and DCM (3 × 5 mL) in sequence. The resin was used for next step without any purification. The peptide chain elongation was completed by repeating deprotection of Fmoc and peptide coupling reaction.

Cleavage

The resin was treated with a solution of 0.5% TFA/DCM (2 mL) for 10 min. Then the mixture was filtered and washed with MeOH (3 × 5 mL) and DCM (3 × 5 mL) in sequence. The filtrate was evaporated under vacuum to afford the crude peptide as a oily liquid.

Purification of Peptides

The crude peptide was purified via RP-HPLC. Analytical HPLC was performed using a J&K C18 (5 μm, 4.6 mm × 250 mm) analytical column. Linear gradients using A: H₂O (0.1% TFA) and B: MeCN (0.1% TFA) were run at a flow rate of 0.8 mL·min⁻¹. Preparative HPLC was performed using a Shimpack Prep-ODS C18 (15 μm, 20 mm × 250 mm) preparative column. Linear gradients using A: H₂O (0.1% TFA) and B: MeCN (0.1% TFA) were run at a flow rate of 8.0 mL·min⁻¹.

H₂N-Tyr-Gly-Gly-Phe-Leu-OH

Colorless solid, yield: 44%. QFT/ESI: m/z calcd. for C₂₈H₃₇N₅O₇ [M+H]⁺: 556.2693, found: 556.2768; for C₂₈H₃₇N₅O₇. [M+Na]⁺: 578.2585, found: 578.2549.

Data Availability Statement

All datasets generated for this study are included in the article/Supplementary Material.

Author Contributions

L-JQ completed SPPS and completed the draft. DL synthesized iodine(III) compounds and dipeptides. KZ completed computational studies. M-TZ guided computational studies. CZ directed the project and finalized the manuscript.

Funding

This work was financially supported by the National Key R&D Program of China (2017YFD020030202), the National Natural Science Foundation of China (21472094 and 21772096), and The Tianjin Natural Science Foundation (17JCYBJC20300).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2020.00183/full#supplementary-material

References

Balasubramanian, T. M., Kendrick, N. C. E., Taylor, M., Marshall, G. R., Hall, J. E., Vodyanov, I., et al. (1981). Synthesis and characterization of the major component of alamethicin. J. Am. Chem. Soc. 103, 6127–6132. doi: 10.1021/ja00410a024

CrossRef Full Text | Google Scholar

Brown, M., Farid, U., and Wirth, T. (2013). Hypervalent iodine reagents as powerful electrophiles. Synlett 24, 424–431. doi: 10.1055/s-0032-1318103

CrossRef Full Text | Google Scholar

Brown, Z. Z., and Schafmeister, C. E. (2008). Exploiting an inherent neighboring group effect of α-amino acids to synthesize extremely hindered dipeptides. J. Am. Chem. Soc. 130, 14382–14383. doi: 10.1021/ja806063k

PubMed Abstract | CrossRef Full Text | Google Scholar

Constable, D. J. C., Dunn, P. J., Hayler, J. D., Humphrey, G. R., Leazer, J. L. Jr., Linderman, R. J., et al. (2007). Key green chemistry research areas—a perspective from pharmaceutical manufacturers. Green Chem. 9, 411–420. doi: 10.1039/B.703488C

CrossRef Full Text | Google Scholar

Coste, J., Frerot, E., Jouin, P., and Castro, B. (1991). Oxybenzotriazole free peptide coupling reagents for N-methylated amino acids. Tetrahedron Lett. 32, 1967–1970. doi: 10.1016/0040-4039(91)85015-W

CrossRef Full Text | Google Scholar

Duan, Y. N., Jiang, S., Han, Y., Sun, B., and Zhang, C. (2016). Recent advances in hypervalent iodine chemistry. Chin. J. Org. Chem. 36, 1973–1984. doi: 10.6023/cjoc201605007

CrossRef Full Text

EI-Faham, A., and Albericio, F. (2011). Peptide coupling reagents, more than a letter soup. Chem. Rev. 111, 6557–6602. doi: 10.1021/cr100048w

CrossRef Full Text | Google Scholar

Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., et al. (2016). Gaussian 16, revision A.03. Wallingford, CT: Gaussian Inc.

Han, Y. C., and Zhang, C. (2018). Synthetic application of water-soluble hypervalent iodine reagents in aqueous media. Tetrahedron Lett. 59, 3052–3057. doi: 10.1016/j.tetlet.2018.06.059

CrossRef Full Text | Google Scholar

Hay, P. J., and Wadt, W. R. (1985). Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals. J. Chem. Phys. 82, 299–310. doi: 10.1063/1.448975

CrossRef Full Text

Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., and Morris, H. R. (1975). Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258, 577–579. doi: 10.1038/258577a0

PubMed Abstract | CrossRef Full Text | Google Scholar

Humphrey, J. M., and Chamberlin, A. R. (1997). Chemical synthesis of natural product peptides: coupling methods for the incorporation of noncoded amino acids into peptides. Chem. Rev. 97, 2243–2266. doi: 10.1021/cr950005s

PubMed Abstract | CrossRef Full Text | Google Scholar

Katritzky, A. R., Todadze, E., Angrish, P., and Draghici, B. (2007). Efficient peptide coupling involving sterically hindered amino acids. J. Org. Chem. 72, 5794–5801. doi: 10.1021/jo0704255

PubMed Abstract | CrossRef Full Text | Google Scholar

Legault, C. Y. (2009). CYLview, 1.0b; Université de Sherbrooke. Sherbrooke, QC: http://www.cylview.org.

Leibfritz, D., Haupt, E., Dubischar, N., Lachmann, H., Oekonomopoulos, R., and Jung, G. (1982). Synthese von 2-methylalanin-peptiden, die pH-Abhängiggkeit ihrer ¹³C-NMR-spektren und eine neue methode zurauswertung über CS-diagramme. Tetrahedron 38, 2165–2181. doi: 10.1016/0040-4020(82)85164-8

CrossRef Full Text | Google Scholar

Li, Y. F., Hari, D. P., Vita, M. V., and Waser, J. (2016). Cyclic hypervalent iodine reagents for atom-transfer reactions: beyond trifluoromethylation. Angew. Chem. Int. Ed. 55, 4436–4454. doi: 10.1002/anie.201509073

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, D., Guo, Y. L., Qu, J., and Zhang, C. (2018). Recyclable hypervalent-iodine-mediated solid-phase peptide synthesis and cyclic peptide synthesis. Beilstein J. Org. Chem. 14, 1112–1119. doi: 10.3762/bjoc.14.97

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, Q., Lan, Y., Liu, J., Li, G., Wu, Y. D., and Lei, A. W. (2009). Revealing a second transmetalation step in the Negishi coupling and its competition with reductive elimination: improvement in the interpretation of the mechanism of biaryl syntheses. J. Am. Chem. Soc. 131, 10201–10210. doi: 10.1021/ja903277d

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, D., He, J. H., and Zhang, C. (2019). Introduction of Hypervalent Iodine Chemistry and Its Application. Univ. Chem, 34, 1–16. doi: 10.3866/PKU.DXHX201806019

CrossRef Full Text

Marenich, A. V., Cramer, C. J., and Truhlar, D. G. (2009). Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B 113, 6378–6396. doi: 10.1021/jp810292n

PubMed Abstract | CrossRef Full Text | Google Scholar

Mocci, F., Uccheddu, G., Frongia, A., and Cerioni, G. (2007). Solution Structure of Some λ³ Iodanes: an ¹⁷O NMR and DFT study. J. Org. Chem. 72, 4163–4168. doi: 10.1021/jo070111h

CrossRef Full Text | Google Scholar

Schoenebeck, F., and Houk, K. N. (2010). Ligand-controlled regioselectivity in palladium-catalyzed cross coupling reactions. J. Am. Chem. Soc. 132, 2496–2497. doi: 10.1021/ja9077528

PubMed Abstract | CrossRef Full Text | Google Scholar

Singh, F. V., and Wirth, T. (2014). Hypervalent iodine-catalyzed oxidative functionalizations including stereoselective reactions. Chem. Asian J. 9, 950–971. doi: 10.1002/asia.201301582

PubMed Abstract | CrossRef Full Text | Google Scholar

Slomczynska, U., Beusen, D. D., Zabrocki, J., Kociolek, K., Redlinski, A., Reusser, F., et al. (1992). Emerimicins III and IV and their Ethylalanine12 epimers. Facilitated chemical-enzymatic synthesis and a qualitative evaluation of their solution structures. J. Am. Chem. Soc. 114, 4095–4106. doi: 10.1021/ja00037a010

CrossRef Full Text | Google Scholar

Tian, J., Gao, W. C., Zhou, D. M., and Zhang, C. (2012). Recyclable hypervalent iodine(III) reagent iodosodilactone as an efficient coupling reagent for direct esterification, amidation, and peptide coupling. Org. Lett. 14, 3020–3023. doi: 10.1021/ol301085v

PubMed Abstract | CrossRef Full Text | Google Scholar

Varvoglis, A. (1997). Hypervalent Iodine in Organic Synthesis. London: Academic Press.

Google Scholar

Wenschuh, H., Beyermann, M., Haber, H., Seydel, J. K., Krause, E., Bienert, M., et al. (1995). Stepwise automated solid phase synthesis of naturally occurring peptaibols using FMOC amino acid fluorides. J. Org. Chem. 60, 405–410. doi: 10.1021/jo00107a020

CrossRef Full Text | Google Scholar

Wirth, T. (2005). Hypervalent iodine chemistry in synthesis: scope and new directions. Angew. Chem. Int. Ed. 44, 3656–3665. doi: 10.1002/anie.200500115

PubMed Abstract | CrossRef Full Text | Google Scholar

Yoshimura, A., and Zhdankin, V. V. (2016). Advances in synthetic applications of hypervalent iodine compounds. Chem. Rev. 116, 3328–3435. doi: 10.1021/acs.chemrev.5b00547

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, C., Liu, S. S., Sun, B., and Tian, J. (2015). Practical peptide synthesis mediated by a recyclable hypervalent iodine reagent and tris(4-methoxyphenyl)phosphine. Org. Lett. 17, 4106–4109. doi: 10.1021/acs.orglett.5b02045

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhdankin, V. V. (2014). Hypervalent Iodine Chemistry: Preparation, Structure, and Synthetic Applications of Polyvalent Iodine Compounds. New York, NY: Wiley.

Google Scholar

Zhdankin, V. V., and Stang, P. J. (2002). Recent developments in the chemistry of polyvalent iodine compounds. Chem. Rev. 102, 2523–2584. doi: 10.1021/cr010003+

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhdankin, V. V., and Stang, P. J. (2008). Chemistry of polyvalent iodine. Chem.Rev. 108, 5299–5358. doi: 10.1021/cr800332c

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, Q. H., and Li, Y. X. (2015). The real role of n-heterocyclic carbene in reductive functionalization of CO₂: an alternative understanding from density functional theory study. J. Am. Chem. Soc. 137, 10182–10189. doi: 10.1021/jacs.5b03651

PubMed Abstract | CrossRef Full Text | Google Scholar